BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 29765039)

  • 1. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
    Hsu JM; Xia W; Hsu YH; Chan LC; Yu WH; Cha JH; Chen CT; Liao HW; Kuo CW; Khoo KH; Hsu JL; Li CW; Lim SO; Chang SS; Chen YC; Ren GX; Hung MC
    Nat Commun; 2018 May; 9(1):1908. PubMed ID: 29765039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
    J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
    Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
    Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
    Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
    Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
    Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
    Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased PD-L1 expression in breast and colon cancer stem cells.
    Wu Y; Chen M; Wu P; Chen C; Xu ZP; Gu W
    Clin Exp Pharmacol Physiol; 2017 May; 44(5):602-604. PubMed ID: 28107571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
    Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
    Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
    Kataoka K
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.
    Liu Z; Li Q; Li K; Chen L; Li W; Hou M; Liu T; Yang J; Lindvall C; Björkholm M; Jia J; Xu D
    Oncogene; 2013 Sep; 32(36):4203-13. PubMed ID: 23045275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.
    Du L; Lee JH; Jiang H; Wang C; Wang S; Zheng Z; Shao F; Xu D; Xia Y; Li J; Zheng Y; Qian X; Li X; Kim HR; Xing D; Liu P; Lu Z; Lyu J
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32860047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
    Chen M; Sharma A; Lin Y; Wu Y; He Q; Gu Y; Xu ZP; Monteiro M; Gu W
    BMC Cancer; 2019 Feb; 19(1):153. PubMed ID: 30770752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RETRACTED: KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway.
    Ruan Z; Liang M; Lai M; Shang L; Deng X; Su X
    Int Immunopharmacol; 2020 Jan; 78():106003. PubMed ID: 31812723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
    Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.